Childhood Pneumonia as a Global Health Priority and the Strategic Interest of The Bill & Melinda Gates Foundation
Clinical Infectious DiseasesPublished 8 March 2012
R. A. Adegbola
Citations49
SJR quartileQ1
SJR score2.99
SNIP2.01
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Studies such as Pneumonia Etiology Research for Child Health (PERCH) that take advantage of new diagnostic technologies are needed to provide an updated and more precise description of the microbial causes of pneumonia and to inform decisions around treatment algorithms and vaccine development and introduction.
Abstract
Pneumonia kills more children than any other disease--more than HIV/AIDS, malaria, and measles combined. Introduction of vaccines against pneumococcus and Haemophilus influenzae type b (the most important causes of severe pneumonia in young children), increasing resistance to antibiotics, and changes in HIV prevalence will likely change patterns of pneumonia etiology in developing countries. Studies such as Pneumonia Etiology Research for Child Health (PERCH) that take advantage of new diagnostic technologies are needed to provide an updated and more precise description of the microbial causes of pneumonia and to inform decisions around treatment algorithms and vaccine development and introduction. In recognition of its importance for global health and especially its significance as an ongoing cause of gross inequity in risks, The Bill & Melinda Gates Foundation has made pneumonia an important part of its global health strategy and PERCH a centerpiece of its Pneumonia Program.
Keywords
MedicineHealth Professions
The LancetGlobal, regional, and national causes of child mortality in 2008: a systematic analysis
3,075 Citations2010Robert E. Black, Simon Cousens +11 more
New estimates for 2008 of the major causes of death in children younger than 5 years in 193 countries are reported to help to focus national programmes and donor assistance.
The LancetBurden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates
2,375 Citations2009Katherine L. O’Brien, Lara J. Wolfson +8 more
The burden of pneumococcal pneumonia is measured by applying the proportion of pneumonia cases caused by S pneumoniae derived from efficacy estimates from vaccine trials to WHO country-specific estimates of all-cause pneumonia cases and deaths, using disease incidence and case-fatality data from a systematic literature review.
The Pediatric Infectious Disease JournalEfficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
2,287 Citations2000Steven Black, Henry R. Shinefield +15 more
This heptavalent pneumococcal conjugate appears to be highly effective in preventing invasive disease in young children and to have a significant impact on otitis media.
New England Journal of MedicineDecline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine
2,243 Citations2003Cynthia G. Whitney, Monica M. Farley +11 more
The use of the pneumococcal conjugate vaccine is preventing disease in young children, for whom the vaccine is indicated, and may be reducing the rate of disease in adults.
New England Journal of MedicineA Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV Infection
1,015 Citations2003Keith P. Klugman, Shabir A. Madhi +4 more
Vaccination with a 9-valent pneumococcal conjugate vaccine reduced the incidence of radiologically confirmed pneumonia among children with and those without HIV infection.
The LancetNeonatal, postneonatal, childhood, and under-5 mortality for 187 countries, 1970–2010: a systematic analysis of progress towards Millennium Development Goal 4
904 Citations2010Julie Knoll Rajaratnam, Jake R Marcus +7 more
This is the first study that uses Gaussian process regression to estimate child mortality, and this technique has better out-of-sample predictive validity than do previous methods and captures uncertainty caused by sampling and non-sampling error across data types.
The LancetEfficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial
899 Citations2005FT Cutts, SMA Zaman +16 more
Pneumococcal conjugate vaccine has high efficacy against radiological pneumonia and invasive pneumococcal disease, and can substantially reduce admissions and improve child survival in this rural African setting.
Clinical Infectious DiseasesThe Epidemiology of Acute Respiratory Tract Infection in Young Children: Comparison of Findings from Several Developing Countries
366 Citations1990B. J. Selwyn
Investigators from 10 countries studied the epidemiology of acute respiratory tract infection among children 0-59 months old to provide interesting and useful data on the epidemiologic dynamics of ARI.
The LancetElimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study
288 Citations2005Richard A. Adegbola, Ousman Secka +12 more
The Gambian Hib immunisation programme reduced the occurrence of Hib disease despite irregular vaccine supply, and has important implications for the introduction of the vaccine into routine immunisation programmes of other developing countries.
JAMAEffectiveness of Haemophilus influenzae Type b Conjugate Vaccine Introduction Into Routine Childhood Immunization in Kenya
184 Citations2006Karen Cowgill, Moses Ndiritu +10 more
In Kenya, introduction of Hib vaccine into the routine childhood immunization program reduced Hib disease incidence among children younger than 5 years to 12% of its baseline level and the impact was not observed until the third year after vaccine introduction.
The Pediatric Infectious Disease JournalImpact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children
162 Citations2000Shabir A. Madhi, Karen L. Petersen +3 more
In children with invasive pneumococcal disease caused by the pediatric serogroups, HIV-infected children have more antibiotic-resistant isolates and have a different clinical presentation than do HIV-un Infected children.
VaccineGlobal use of Haemophilus influenzae type b conjugate vaccine
46 Citations2010Linda R. Ojo, Rosalyn O’Loughlin +8 more
Progress in global use of Hib vaccines included in national immunization schedules is reported and the number of countries using Hib vaccine increased from 89/193 in 2004 to 158/193 by the end of 2009.
PLoS MedicineWhat Are the Implications for Childhood Pneumonia of Successfully Introducing Hib and Pneumococcal Vaccines in Developing Countries?
43 Citations2008J. Anthony G. Scott, Mike English
Bulletin of the World Health OrganizationChildhood pneumonia - preventing the world's biggest killer of children
34 Citations2007Brian M Greenwood
The meeting was attended by experts in the four areas that offer the best prospects for pneumonia control – case management (IMCI), vaccination (Hib and pneumococcal), environmental health (reduced indoor air pollution) and nutrition, and urged that the global response to pneumonia mortality be balanced and equitable.
ScienceSome Neglected Diseases Are More Neglected Than Others
31 Citations2009Martin Enserink
The first global study tracking spending on research and development for "neglected diseases" finds that the battle against dengue is relatively well-funded, whereas pneumonia, meningitis, and diarrhea get mere table crumbs.
Clinical Infectious DiseasesProgress and Future Challenges in Coordinated Surveillance and Detection of Pneumococcal and Hib Disease in Developing Countries
28 Citations2009Orin S. Levine, Thomas Cherian +2 more
This poster presents a poster presented at the 2016 World Health Organization conference on Immunizations, Vaccines, and Biologics entitled “Preparation and Administration of Immunizations for PneumoADIP and Hib: Foundations of a Clinical Trial.”